Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Publication in Accordance With Article 14 of the Belgian Law if 2 May 2007 Regarding the Publication of Major Shareholdings (The



Publication in Accordance With Article 14 of the Belgian Law if 2 May 2007
Regarding the Publication of Major Shareholdings (The "Transparency Law")

GHENT, Belgium, Oct. 18, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:
ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2
May 2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from Gimv NV and
Biotech Fonds Vlaanderen NV.

The above shareholders notified that they have dropped below the 3% threshold
and now have sold their complete stake in Ablynx.

Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life
Sciences 2004 NV. Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer
Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV are acting in
mutual agreement. The Flemish Region in Belgium is the ultimate shareholder of
Biotech Fonds Vlaanderen NV.

Full versions of all transparency notifications are available on the website
of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and six Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is
headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

Pdf version of the press release:
http://hugin.info/137912/R/1736647/582049.pdf

CONTACT: For more information, please contact Ablynx:
         Dr Edwin Moses
         Chairman and CEO
         t: +32 (0)9 262 00 07
         m: +44 (0)7771 954 193 /
         +32 (0)473 39 50 68
         e:  edwin.moses@ablynx.com
        
         Marieke Vermeersch
         Associate Director Investor Relations
         t: +32 (0)9 262 00 82
         m: +32 (0)479 49 06 03
         e:  marieke.vermeersch@ablynx.com
        
        
         Media relations for Ablynx: Consilium Strategic Communications
         Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
         t: +44 207 920 2345
         e: ablynx@consilium-comms.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement